+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Soft Tissue Sarcoma (STS) - Market Insights, Epidemiology, and Market Forecast - 2030

  • ID: 4871914
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 447 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Aadi Bioscience
  • Bayer, Loxo Oncology
  • Eisai
  • Gem Pharmaceuticals
  • Janssen Biotech
  • Nanobiotix
  • MORE
‘Soft Tissue Sarcoma (STS) - Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of STS in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease, but the affected individuals may notice slow-growing, painless mass in the affected area.

According to the publisher's, STS has various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to the majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Soft Tissue Sarcoma (STS) - Disease Understanding and Treatment Algorithm

Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease's clinical course.

Soft Tissue Sarcoma (STS) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM, Type-specific Incidence Cases of Soft Tissue Sarcoma (STS) in the 7MM, Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States, Total Incident Cases of STS including GIST in the United States and Incidence of STS by Extremities (%) in the 7MM scenario of STS in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017-2030.

According to the publisher's, the total incident population of Soft Tissue Sarcoma (STS) in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, the United States accounts for the highest number of cases of STS. In 2017, there were 12,390 incident cases of STS - which did not include GIST cases - in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total incident population of STS to 17,480 in 2017.

Soft Tissue Sarcoma (STS) Drug Chapters

STS is a heterogeneous group of malignancies and relatively rare that are characterized by mesodermal differentiation. It is primarily encountered in adults but can affect patients of any age. There are many histologic subtypes, and the malignancy can be low or high grade. Soft tissue sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.

The emerging therapies are classified into four categories based on their line of therapy. The upcoming first-line therapies that are going to be launched in the forecasted period includes, AL3818 (anlotinib) and Fibromun. The second-line emerging therapies include Vigil in combination with irinotecan and temozolomide, AL3818, GSK 3377794, Ripretinib (DCC-2618), Tazemetostat, Abemaciclib, Pembrolizumab, Crizotinib, ABI-009, and SRA737. The third-line emerging therapies include Avapritinib, Cabozantinib, and Selinexor. The fourth-line emerging therapies include Avapritinib, TAS-116, Crenolanib, and Ripretinib.

Soft Tissue Sarcoma (STS) Market Outlook

According to the publisher, the total market size of Soft Tissue Sarcoma (STS) excluding GIST in seven major markets was USD 246.7 million in 2017. The market size of STS is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounts for the highest market size of STS. In 2017, the market size of STS (excluding GIST) was found to be USD 142.18 million.

Among EU5, Germany had the highest market size in 2017 with revenue USD 22.06 million, followed by Italy with revenue USD 18.84 million. The market size of STS (excluding GIST) in Japan was found to be USD 17.60 million in 2017.

Soft Tissue Sarcoma (STS) Drugs Uptake

The current market size of STS is mainly attributed to Votrient, Yondelis, Halaven, and various anthracycline and non-anthracycline regimens. The market size of GIST in the United States was found to be USD 119.7 million in 2017 and expected to increase during the forecast period (2020-2030) due to potential therapies Vitrakvi, Rozlytrek, Avapritinib, Ripretinib and others.

Soft Tissue Sarcoma (STS) Report Insights
  • Patient Population by total incident cases
  • Type-specific incident cases of STS
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Soft Tissue Sarcoma (STS) Report Key Strengths
  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Soft Tissue Sarcoma (STS) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT Analysis
  • Access and Reimbursement
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Soft Tissue Sarcoma (STS) market
  • Organize sales and marketing efforts by identifying the best opportunities for Soft Tissue Sarcoma (STS) market
  • To understand the future market competition in the Soft Tissue Sarcoma (STS) market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aadi Bioscience
  • Bayer, Loxo Oncology
  • Eisai
  • Gem Pharmaceuticals
  • Janssen Biotech
  • Nanobiotix
  • MORE
1. Key Insights

2. Executive Summary of Soft-Tissue Sarcoma (STS)

3. Soft-Tissue Sarcomas (STS) Market Overview at a Glance
3.1. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2017
3.2. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2030

4. Soft-Tissue Sarcomas (STS): Disease Background and Overview
4.1. Introduction
4.2. Types of Soft-Tissue Sarcomas (STS)
4.3. The Molecular Biology of Soft-Tissue Sarcomas (STS)
4.4. Stages of Soft-Tissue Sarcomas (STS)
4.5. Diagnosis of Soft-Tissue Sarcomas (STS)
4.5.1. Medical History and Physical Exam
4.5.2. Imaging Tests
4.5.3. Biopsy
4.5.4. Pathological diagnosis of soft tissue sarcomas
4.5.5. Proposed Diagnostic Guidelines

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Epidemiology and Market Methodology
5.3. 7MM Incident Patient Population of Soft Tissue Sarcoma (STS)

6. Case Reports
6.1. Neo-adjuvant chemotherapy for radiation-associated soft-tissue sarcoma (RAS): A case report
6.2. Soft-Tissue Sarcoma Masquerading as a Hematoma
6.3. Neo-adjuvant chemotherapy for primary sarcoma of the breast: a case report

7. Country Wise-Epidemiology of Soft Tissue Sarcoma (STS)
7.1. United States Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United States
7.1.3. Type-Specific Incidence of STS in the United States
7.1.4. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
7.1.5. Total Incident Cases of STS including GIST in the United States
7.1.6. Incidence of STS by Extremities (%) in the United States
7.2. EU5 Epidemiology
7.2.1. Germany
7.2.1.1. Assumptions and Rationale
7.2.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Germany
7.2.1.3. Gender-Specific Incidence of STS in Germany
7.2.1.4. Type-Specific Incidence of STS in Germany
7.2.1.5. Age-Specific Incidence of STS in Germany
7.2.1.6. Stage-Specific Incidence of STS in Germany
7.2.1.7. Incidence of STS by Extremities (%) in Germany
7.2.2. France
7.2.2.1. Assumptions and Rationale
7.2.2.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in France
7.2.2.3. Gender-Specific Incidence of STS in France
7.2.2.4. Type-Specific Incidence of STS in France
7.2.2.5. Age-Specific Incidence of STS in France
7.2.2.6. Stage-Specific Diagnosed Incidence of STS in France
7.2.2.7. Incidence of STS by Extremities (%) in France
7.2.3. Italy
7.2.3.1. Assumptions and Rationale
7.2.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Italy
7.2.3.3. Gender-Specific Incidence of STS in Italy
7.2.3.4. Type-Specific Incidence of STS in Italy
7.2.3.5. Age-Specific Incidence of STS in Italy
7.2.3.6. Stage-Specific Diagnosed Incidence of STS in Italy
7.2.3.7. Incident of STS by Extremities (%) in Italy
7.2.4. Spain
7.2.4.1. Assumptions and Rationale
7.2.4.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Spain
7.2.4.3. Gender-Specific Incidence of STS in Spain
7.2.4.4. Type-Specific Incidence of STS in Spain
7.2.4.5. Age-Specific Incidence of STS in Spain
7.2.4.6. Stage-Specific Incidence of STS in Spain
7.2.4.7. Incident of STS by Extremities (%) in Spain
7.2.5. United Kingdom
7.2.5.1. Assumptions and Rationale
7.2.5.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United Kingdom
7.2.5.3. Gender-Specific Incidence of STS in the United Kingdom
7.2.5.4. Type-Specific Incidence of STS in the United Kingdom
7.2.5.5. Age-Specific Incidence of STS in the United Kingdom
7.2.5.6. Stage-Specific Diagnosed Incidence of STS in the United Kingdom
7.2.5.7. Incident of STS by Extremities (%) in the United Kingdom
7.3. Japan Epidemiology
7.3.1. Assumptions and Rationale
7.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Japan
7.3.3. Gender-Specific Incidence of STS in Japan
7.3.4. Type-Specific Incidence of STS in Japan
7.3.5. Age-Specific Incidence of STS in Japan
7.3.6. Stage-Specific Incidence of STS in Japan
7.3.7. Incident of STS by Extremities (%) in Japan

8. Treatment and Management of Soft Tissue Sarcoma (STS)
8.1. Stage-wise Treatment
8.2. Treatment Algorithms
8.3. Treatment Guidelines
8.3.1. UK guidelines for the management of soft tissue sarcomas
8.3.2. NCCN guidelines for the management of soft tissue sarcomas
8.3.3. Soft Tissue and Visceral Sarcomas: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

9. Unmet Needs

10. Marketed Drugs
10.1. Halaven (Eribulin Mesylate): Eisai
10.1.1. Product Description
10.1.2. Regulatory Milestones
10.1.3. Clinical Development
10.1.4. Ongoing Current Pipeline Activity
10.1.5. Safety and efficacy
10.1.6. Product Profile
10.2. Gleevec (Imatinib Mesylate): Novartis
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Clinical Development
10.2.4. Safety and efficacy
10.2.5. Product Profile
10.3. Yondelis (Trabectedin): Pharma Mar
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Clinical Development
10.3.4. Safety and efficacy
10.3.5. Product Profile
10.4. Lartruvo (Olaratumab): Eli Lilly
10.4.1. Product Description
10.4.2. Regulatory Milestones
10.4.3. Clinical Development
10.4.4. Safety and efficacy
10.4.5. Product Profile
10.5. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Clinical Development
10.5.4. Safety and efficacy
10.5.5. Product Profile
10.6. Stivarga (Regorafenib): Bayer
10.6.1. Product Description
10.6.2. Regulatory Milestones
10.6.3. Clinical Development
10.6.4. Ongoing Current Pipeline Activity
10.6.5. Safety and efficacy
10.6.6. Product Profile
10.7. Sutent (Sunitinib malate): Pfizer
10.7.1. Product Description
10.7.2. Regulatory Milestones
10.7.3. Clinical Development
10.7.4. Safety and efficacy
10.7.5. Product Profile
10.8. Votrient (Pazopanib): GlaxoSmithKline/Novartis
10.8.1. Product Description
10.8.2. Regulatory Milestones
10.8.3. Clinical Development
10.8.4. Ongoing Current Pipeline Activity
10.8.5. Safety and efficacy
10.8.6. Product Profile
10.9. Vincristine Sulfate: Hospira
10.9.1. Product Description
10.9.2. Regulatory Milestones
10.9.3. Product Profile
10.10. Rozlytrek (Entrectinib): Roche (Genentech)
10.10.1. Product Description
10.10.2. Regulatory Milestones
10.10.3. Safety and Efficacy of Rozlytrek
10.10.4. Clinical trial information
10.10.5. Product Profile

11. Emerging Drugs
11.1. Key Cross Competition
11.2. Avapritinib (BLU-285): Blueprint Medicines Corporation
11.2.1. Product Description
11.2.2. Other Development Activities
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. Vigil (In combination with irinotecan and temozolomide): Gradalis
11.3.1. Product Description
11.3.2. Other Development Activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
11.4.1. Product Description
11.4.2. Other Development Activities
11.4.3. Clinical Development
11.4.4. Clinical Trials Information
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.5. Selinexor: Karyopharm Therapeutics
11.5.1. Product Description
11.5.2. Other Development Activities
11.5.3. Clinical Development
11.5.4. Clinical Trials Information
11.5.5. Safety and Efficacy
11.5.6. Product Profile
11.6. Aldoxorubicin (INNO-206): CytRx
11.6.1. Product Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Safety and Efficacy
11.6.6. Product Profile
11.7. Ripretinib (DCC-2618): Deciphera Pharmaceuticals
11.7.1. Product Description
11.7.2. Other Development Activities
11.7.3. Clinical Development
11.7.4. Clinical Trials Information
11.7.5. Safety and Efficacy
11.7.6. Product Profile
11.8. Fibromun (In combination with Doxorubicin): Philogen
11.8.1. Product Description
11.8.2. Other Development Activities
11.8.3. Clinical Development
11.8.4. Clinical Trials Information
11.8.5. Product Profile
11.9. Hensify (NBTXR3): Nanobiotix
11.9.1. Product Description
11.9.2. Other Development Activities
11.9.3. Clinical Development
11.9.4. Clinical Trials Information
11.9.5. Safety and efficacy
11.9.6. Product Profile
11.10. Crenolanib: Arog Pharmaceuticals
11.10.1. Product Description
11.10.2. Other Development Activities
11.10.3. Clinical Development
11.10.4. Clinical Trials Information
11.10.5. Safety and Efficacy
11.10.6. Product Profile
11.11. TAS-116: Taiho Pharmaceutical
11.11.1. Product Description
11.11.2. Clinical Development
11.11.3. Clinical Trials Information
11.11.4. Safety and Efficacy
11.11.5. Product Profile
11.12. GSK3377794: GlaxoSmithKline/ Adaptimmune
11.12.1. Product Description
11.12.2. Other Development Activities
11.12.3. Clinical Development
11.12.4. Clinical Trials Information
11.12.5. Safety and Efficacy
11.12.6. Product Profile
11.13. ADP-A2M4: Adaptimmune
11.13.1. Product Description
11.13.2. Other Development Activities
11.13.3. Clinical Development
11.13.4. Clinical Trials Information
11.13.5. Safety and Efficacy
11.13.6. Product Profile
11.14. Tazemetostat (EPZ-6438): Epizyme
11.14.1. Product Description
11.14.2. Other Developmental Activities
11.14.3. Clinical Development
11.14.4. Clinical Trials Information
11.14.5. Safety and Efficacy
11.14.6. Product Profile
11.15. AMG 337: NantPharma/ Amgen
11.15.1. Product Description
11.15.2. Other Development Activities
11.15.3. Clinical Development
11.15.4. Clinical Trials Information
11.15.5. Safety and Efficacy
11.15.6. Product Profile
11.16. GB226/APL-501: Genor Biopharma /Apollomics (Previously CBT Pharmaceuticals)
11.16.1. Product Description
11.16.2. Other Development Activities
11.16.3. Clinical Development
11.16.4. Clinical Trials Information
11.16.5. Product Profile
11.17. Camsirubicin: Monopar Therapeutics /Gem Pharmaceuticals
11.17.1. Product Description
11.17.2. Other Development Activities
11.17.3. Clinical Development
11.17.4. Clinical Trials Information
11.17.5. Safety and Efficacy
11.17.6. Product Profile
11.18. LTX-315: Lytix Biopharma
11.18.1. Product Description
11.18.2. Other Development Activities
11.18.3. Clinical Development
11.18.4. Clinical Trials Information
11.18.5. Safety and Efficacy
11.18.6. Product Profile
11.19. Abemaciclib (LY2835219): Eli Lilly and Company
11.19.1. Product Description
11.19.2. Other Development Activities
11.19.3. Clinical Development
11.19.4. Clinical Trials Information
11.19.5. Safety and Efficacy
11.19.6. Product Profile
11.20. Pembrolizumab: Merck Sharp & Dohme Corp.
11.20.1. Product Description
11.20.2. Other Development Activities
11.20.3. Clinical Development
11.20.4. Clinical Trials Information
11.20.5. Safety and Efficacy
11.20.6. Product Profile
11.21. Crizotinib (PF-02341066): Pfizer
11.21.1. Product Description
11.21.2. Other Development Activities
11.21.3. Clinical Development
11.21.4. Clinical Trials Information
11.21.5. Safety and Efficacy
11.21.6. Product Profile
11.22. ABI-009: Aadi Bioscience
11.22.1. Product Description
11.22.2. Other Development Activities
11.22.3. Clinical Development
11.22.4. Clinical Trials Information
11.22.5. Safety and Efficacy
11.22.6. Product Profile
11.23. Nivolumab: Bristol-Myers Squibb
11.23.1. Product Description
11.23.2. Other Development Activities
11.23.3. Clinical Development
11.23.4. Clinical Trials Information
11.23.5. Safety and Efficacy
11.23.6. Product Profile
11.24. Sorafenib Tosylate: Bayer
11.24.1. Product Description
11.24.2. Clinical Development
11.24.3. Clinical Trials Information
11.24.4. Safety and Efficacy
11.24.5. Product Profile
11.25. Doxorubicin with AGEN1884 and AGEN2034: Agenus
11.25.1. Product Description
11.25.2. Clinical Development
11.25.3. Clinical Trials Information
11.25.4. Product Profile
11.26. Apatinib Mesylate (In Combination with Doxorubicin and Ifosfamide: Jiangsu HengRui Medicine
11.26.1. Product Description
11.26.2. Clinical Development
11.26.3. Clinical Trials Information
11.26.4. Product Profile
11.27. Atezolizumab: Roche Pharma AG
11.27.1. Product Description
11.27.2. Clinical Development
11.27.3. Clinical Trials Information
11.27.4. Product Profile
11.28. Spartalizumab (PDR001): Novartis Pharmaceuticals
11.28.1. Product Description
11.28.2. Other Development Activities
11.28.3. Clinical Development
11.28.4. Clinical Trials Information
11.28.5. Product Profile
11.29. Iclusig (Ponatinib): Takeda
11.29.1. Product Description
11.29.2. Other Development Activities
11.29.3. Clinical Development
11.29.4. Clinical Trials Information
11.29.5. Safety and Efficacy
11.29.6. Product Profile
11.30. Temozolomide (Temodar): Merck
11.30.1. Product Description
11.30.2. Other Developmental Activities:
11.30.3. Clinical Development
11.30.4. Clinical trial information
11.30.5. Product Profile
11.31. Cabozantinib: Exelixis
11.31.1. Product Description
11.31.2. Other Developmental Activities:
11.31.3. Clinical Development
11.31.4. Clinical trial information
11.31.5. Safety and Efficacy
11.31.6. Product Profile
11.32. Avelumab: Merck KGaA
11.32.1. Product Description
11.32.2. Other Developmental Activities:
11.32.3. Clinical Development
11.32.4. Clinical trial information
11.32.5. Product Profile
11.33. Lenvatinib (In Combination with Everolimus): Eisai
11.33.1. Product Description
11.33.2. Other Development Activities
11.33.3. Clinical Development
11.33.4. Clinical Trials Information
11.33.5. Product Profile
11.34. SRA737: Sierra Oncology
11.34.1. Product Description
11.34.2. Other Development Activities
11.34.3. Clinical Development
11.34.4. Clinical Trials Information
11.34.5. Safety and Efficacy
11.34.6. Product Profile
11.35. Nab-paclitaxel: Celgene
11.35.1. Product Description
11.35.2. Other Developmental Activities
11.35.3. Clinical Development
11.35.4. Clinical Trials Information
11.35.5. Safety and Efficacy
11.35.6. Product Profile
11.36. Afatinib: Boehringer Ingelheim
11.36.1. Product Description
11.36.2. Other Development Activities
11.36.3. Clinical Development
11.36.4. Clinical Trials Information
11.36.5. Safety and Efficacy
11.36.6. Product Profile
11.37. IMCnyeso (GSK01): GlaxoSmithKline/Immunocore
11.37.1. Product Description
11.37.2. Other Development Activities
11.37.3. Clinical Development
11.37.4. Clinical Trials Information
11.37.5. Product Profile
11.38. CAR-T/TCR-T Cell Immunotherapy: Shenzhen BinDeBio
11.38.1. Product Description
11.38.2. Other Development Activities
11.38.3. Clinical Development
11.38.4. Clinical Trials Information
11.38.5. Product Profile
11.39. Epirubicin Micelle (NC-6300; K-912): NanoCarrier
11.39.1. Product Description
11.39.2. Other Development Activities
11.39.3. Clinical Development
11.39.4. Clinical Trials Information
11.39.5. Safety and Efficacy
11.39.6. Product Profile
11.40. Copanlisib (BAY806946): Bayer
11.40.1. Product Description
11.40.2. Other Developmental Activities
11.40.3. Clinical Development
11.40.4. Clinical Trials Information
11.40.5. Product Profile
11.41. PLX9486: Plexxikon
11.41.1. Product Description
11.41.2. Clinical Development
11.41.3. Clinical Trials Information
11.41.4. Safety and Efficacy
11.41.5. Product Profile
11.42. BA3021: BioAtla
11.42.1. Product Description
11.42.2. Other Developmental Activities
11.42.3. Clinical Development
11.42.4. Clinical Trials Information
11.42.5. Product Profile
11.43. Tinostamustine (EDO-S101): Mundipharma-EDO GmbH
11.43.1. Product Description
11.43.2. Other Developmental Activities
11.43.3. Clinical Development
11.43.4. Clinical Trials Information
11.43.5. Safety and Efficacy
11.43.6. Product Profile
11.44. TBI-1301 (NY-ESO-1 T cell Receptor Gene Transduced Autologous T Lymphocytes): Takara Bio.
11.44.1. Product Description
11.44.2. Other Developmental Activities
11.44.3. Clinical Development
11.44.4. Clinical Trials Information
11.44.5. Safety and Efficacy
11.44.6. Product Profile
11.45. Ramucirumab (LY3009806): Eli Lilly and Company
11.45.1. Product Description
11.45.2. Clinical Development
11.45.3. Clinical Trials Information
11.45.4. Product Profile
11.46. TB-403: Oncurious NV
11.46.1. Product Description
11.46.2. Other Developmental Activities
11.46.3. Clinical Development
11.46.4. Clinical Trials Information
11.46.5. Product Profile
11.47. TLC178: Taiwan Liposome Company
11.47.1. Product Description
11.47.2. Other Development Activities
11.47.3. Clinical Development
11.47.4. Clinical Trials Information
11.47.5. Safety and Efficacy
11.47.6. Product Profile
11.48. Talimogene Laherparepvec (T-VEC): Amgen
11.48.1. Product Description
11.48.2. Other Developmental Activities
11.48.3. Clinical Development
11.48.4. Clinical Trials Information
11.48.5. Safety and Efficacy
11.48.6. Product Profile
11.49. MEK162: Array BioPharma
11.49.1. Product Description
11.49.2. Clinical Development
11.49.3. Clinical Trials Information
11.49.4. Safety and Efficacy
11.49.5. Product Profile
11.50. Neoadjuvant Durvalumab and Tremelimumab: AstraZeneca
11.50.1. Product Description
11.50.2. Clinical Development
11.50.3. Clinical Trials Information
11.50.4. Safety and Efficacy
11.50.5. Product Profile
11.51. Selpercatinib (LOXO-292): Eli Lilly/Loxo Oncology
11.51.1. Product Description
11.51.2. Other Development Activities
11.51.3. Clinical Development
11.51.4. Clinical Trials Information
11.51.5. Product Profile

12. Soft Tissue Sarcoma (STS): 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of metastatic Soft Tissue Sarcoma (STS) in the 7MM
12.3. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the 7MM

13. Market Outlook: The United States
13.1. United States Market Size
13.1.1. Total market size of Soft Tissue Sarcoma (STS)*
13.1.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United States

14. Market Outlook: Europe
14.1. Germany
14.1.1. The total market size of Soft Tissue Sarcoma (STS)
14.1.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Germany
14.2. France
14.2.1. Total Market size of Soft Tissue Sarcoma (STS)
14.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in France
14.3. Italy
14.3.1. Total Market size of Soft Tissue Sarcoma (STS)
14.3.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Italy
14.4. Spain
14.4.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
14.4.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Spain
14.5. United Kingdom
14.5.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
14.5.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United Kingdom (UK)

15. Market Outlook: Japan
15.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
15.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Japan
15.2.1. Market Size of metastatic Soft Tissue Sarcoma (STS) by First-line of Therapies in Japan
15.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Second-Line & Later Line Therapies in Japan

16. Access and Reimbursement Overview of Soft-Tissue Sarcoma (STS)

17. Market Drivers

18. Market Barriers

19. SWOT Analysis

20. Appendix
20.1. Report Methodology

21. Publisher Capabilities

22. Disclaimer

23. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Blueprint Medicines Corporation
  • Gradalis
  • Advenchen Laboratories
  • Karyopharm Therapeutics
  • CytRx
  • Deciphera Pharmaceuticals
  • Philogen S.p.A
  • GlaxoSmithKline
  • Adaptimmune
  • Epizyme, Inc.
  • NantPharma
  • Genor Biopharma Co., Ltd/.Apollomics, Inc.
  • Gem Pharmaceuticals
  • Lytix Biopharma AS
  • NanoCarrier Co., Ltd.
  • Eli Lilly and Company
  • Merck Sharp & Dohme Corp.
  • Pfizer
  • Aadi Bioscience
  • Bristol-Myers Squibb/Ono Pharmaceuticals
  • Sierra Oncology
  • Nanobiotix
  • Bayer
  • Eisai
  • Novartis
  • Pfizer
  • Janssen Biotech
  • GSK
  • Bayers
  • Pfizer
  • Eli Lilly
  • Bayer, Loxo Oncology
Note: Product cover images may vary from those shown
Adroll
adroll